Verve Therapeutics’ VERVE-102 shows early success in lowering LDL cholesterol by 55% with a single dose, offering a potential one-time gene editing treatment for familial hypercholesterolemia...
MIT engineers have developed a gene circuit that precisely controls gene expression, offering potential breakthroughs in gene therapy for disorders like fragile X syndrome. This advancement helps ensure therapeutic genes are expressed at optimal levels, minimizing risks and paving the way for more effective treatments...
Avance Biosciences is excited to exhibit at the ASGCT 2025 conference in New Orleans, LA, from May 13–17, 2025. Join us to explore our expert bioanalytical solutions for gene and cell therapy development. Visit booth #750 to learn how we can support your therapeutic advancements...
Avance Biosciences™ is joining the 2025 AAPS National Biotechnology Conference to showcase our expertise in biological assay development, validation, and sample testing. Visit our booth to learn more about our innovative solutions and explore potential collaborations in drug development...
A new preclinical study shows that Imiquimod enhances immune responses to an HIV DNA vaccine, offering promising implications for nucleic acid vaccine design and innate immune modulation strategies...
Avance Biosciences is excited to participate in the World Vaccine Congress 2025, showcasing our advanced solutions in vaccine development, bioanalytics, and regulatory compliance. Join us to explore collaboration opportunities and learn how our services can support your vaccine research and clinical trials...
The FDA is phasing out animal testing for monoclonal antibodies and other drugs, turning to AI, lab-grown human tissues, and global safety data to streamline development, cut costs, and improve patient safety...
A new study offers hope for improving CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia (B-ALL), a cancer with high relapse rates. Researchers have developed an innovative approach involving a TIM-3 decoy that prevents immune evasion by leukemia cells...
Avance Biosciences contributed critical RNA sequencing to the development of MV-014-212, a novel intranasal COVID-19 vaccine. In preclinical trials, MV-014-212 showed significant promise by reducing viral shedding and eliciting a broad immune response, including protection against multiple variants of concern...
Avance Biosciences offers CLIA-compliant testing services to ensure accurate, reliable data throughout drug development. From biomarker validation to regulatory support, our expertise helps biopharmaceutical companies advance clinical trials and bring innovative biologic treatments to market with confidence...
